BRAIN Biotech AG: BRAIN Group expands its food enzyme business with the acquisition of a majority of Breatec B.V. and Comix
BRAIN Biotech AG / Key word(s): Takeover
BRAIN Group expands its food enzyme business with the acquisition of a majority of Breatec B.V. and Comix
Zwingenberg, Germany, February 1st, 2022. BRAIN Biotech AG ("BRAIN") has acquired an initial stake of 62% in Breatec B.V. including the Comix business via Weriol Group B.V., Nieuwkuijk, Netherlands, to expand its food related enzyme business. A call/put structure has been negotiated to aquire the business in full latest until the end of the first quarter 2027. The initial purchase price is EUR 3.7 million and will be financed out of existing cash. Breatec B.V. had a turnover of around EUR 7.0 million in calendar year 2021 and was EBITDA positive.
Michael Schneiders, Head of IR & Sustainability
BRAIN Biotech AG
Investor Relations Office
End of ad hoc announcement
Information and Explanation of the Issuer to this News:
BRAIN Biotech AG ('BRAIN') is a leading European industrial biotechnology specialist with a focus on nutrition, health and the environment. As a technology and solutions provider the company supports the biologization of industries with bio-based products and processes. From contract R&D with industrial partners to advancing own disruptive incubator projects and customized enzyme products, BRAIN's broad cutting-edge biotech expertise and its agile teams are key to success.
01-Feb-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||BRAIN Biotech AG|
|Darmstädter Straße 34-36|
|Phone:||+49 (0) 62 51 / 9331-0|
|Fax:||+49 (0) 62 51 / 9331-11|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1275447|
|End of Announcement||DGAP News Service|